<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/0F15002C-C70C-4AD9-B432-E950F6B2FDFD"><gtr:id>0F15002C-C70C-4AD9-B432-E950F6B2FDFD</gtr:id><gtr:name>European Institute of Oncology</gtr:name><gtr:address><gtr:line1>Via Ripamonti 435</gtr:line1><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:department>Medical and Human Sciences</gtr:department><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/0F15002C-C70C-4AD9-B432-E950F6B2FDFD"><gtr:id>0F15002C-C70C-4AD9-B432-E950F6B2FDFD</gtr:id><gtr:name>European Institute of Oncology</gtr:name><gtr:address><gtr:line1>Via Ripamonti 435</gtr:line1><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/6E67417F-B80E-4C95-BF96-FB92B017EF03"><gtr:id>6E67417F-B80E-4C95-BF96-FB92B017EF03</gtr:id><gtr:firstName>John</gtr:firstName><gtr:otherNames>Michael</gtr:otherNames><gtr:surname>Gardiner</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/2C9BD9EC-D907-459F-B3C5-90B22288D628"><gtr:id>2C9BD9EC-D907-459F-B3C5-90B22288D628</gtr:id><gtr:firstName>Gordon</gtr:firstName><gtr:otherNames>Charles</gtr:otherNames><gtr:surname>Jayson</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0902173"><gtr:id>42F5F16A-3E25-4098-B48A-8933101C36A1</gtr:id><gtr:title>Development of Anti-Angiogenic Oligosaccharides</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0902173</gtr:grantReference><gtr:abstractText>Tumour growth is critically dependent on the formation of new blood vessels, which provide oxygen and nutrients to the tumour. Clinical trials have demonstrated that drugs, which inhibit blood vessel formation, can improve the outcome of patients with several different types of cancer. 

We have developed a new drug for the treatment of ovarian cancer that works by blocking blood vessel formation inside the tumour. The drug blocks three of the critical growth factors (like hormones) that drive blood vessel formation in ovarian cancer. The drug emerged from a novel chemistry research programme that allows us to make custom-designed oligosaccharides (complex sugar molecules) that block growth factors from generating new blood vessels in a cancer. 

In the laboratory the oligosaccharides block blood vessel formation in several different types of experiments. In this research project we will continue our research on these new molecules by testing several different oligosaccharides in experiments that will test the safety and effectiveness of the drugs. At the end of this grant we will have identified the lead molecule and will be ready to move the drug towards clinical trials.</gtr:abstractText><gtr:technicalSummary>Randomized trials have demonstrated that anti-angiogenic VEGF inhibitors improve survival in several malignancies. However, the benefit is of limited duration and the drugs can be toxic. Thus there is a clear need to develop new anti-angiogenic agents.

Heparan sulfate (HS), a linear disaccharide polymer, is essential for the biological activity of most angiogenic cytokines. In an MRC Milstein grant-funded project we have evaluated a series of defined HS oligosaccharides synthesised using novel and scalable chemistry. A lead molecule has been identified that significantly inhibits the activity of a number of angiogenic targets to reduce endothelial tube formation, migration and proliferation in vitro. Previous data demonstrated anti-angiogenic activity with structurally related compounds, in vivo.
In this application the molecule will progress through defined developmental milestones to generate a lead candidate that has the required potency and suitable ADMET characteristics to support progression into late stage pre-clinical development and phase I clinical trial evaluation.</gtr:technicalSummary><gtr:fund><gtr:end>2013-02-28</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2010-05-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>820890</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>European Institute of Oncology (IEO)</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>biosensor evaluation of HS oligosaccharides</gtr:description><gtr:id>E8330555-BF9B-4B7E-9251-1BB0E3E50795</gtr:id><gtr:impact>The data will contribute to our MRC DPFS output</gtr:impact><gtr:partnerContribution>Professor Marco Presta is measuring the KD and on/off rates of oligosaccharides with respect to angiogenic cytokines Professor Marco Presta is measuring the KD and on/off rates of oligosaccharides with respect to angiogenic cytokines</gtr:partnerContribution><gtr:piContribution>We have generated the oligosaccharides and evaluated them in vitro and in vivo</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>European Institute of Oncology (IEO)</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>biosensor evaluation of HS oligosaccharides</gtr:description><gtr:id>D0A84611-D78B-46AA-A73C-431871A09057</gtr:id><gtr:impact>The data will contribute to our MRC DPFS output</gtr:impact><gtr:partnerContribution>Professor Marco Presta is measuring the KD and on/off rates of oligosaccharides with respect to angiogenic cytokines Professor Marco Presta is measuring the KD and on/off rates of oligosaccharides with respect to angiogenic cytokines</gtr:partnerContribution><gtr:piContribution>We have generated the oligosaccharides and evaluated them in vitro and in vivo</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>patient group</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>010A395A-CC2C-4FE5-B5F0-19DED5D4FC4B</gtr:id><gtr:impact>i regularly talk to patient groups or interested lay members or relatives

I am now medical patron of the cancer charity &amp;quot;Chai Cancer Care&amp;quot; in Manchester</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010,2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>school lectures</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>C50EBDE8-30C0-491F-8CAD-C8D8EC00551D</gtr:id><gtr:impact>I talk every year at different schools. The students can contact me about medicine after that.

advise students on medical school entry and meet and talk with prospective med students</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>we have developed and patented (i) the complete scalable synthesis of iduronate and (ii) the complete synthesis of heparan sulphate oligosaccharides. this is 2 patents</gtr:description><gtr:id>90DE6ABE-7A06-408C-836C-DFE8CAB7F7CC</gtr:id><gtr:impact>Cancer Research Technology (linked with CRUK) are managing the IP on behalf of the University of Manchester and MRC. They are outlicensing the IP to pharmaceutical companies</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:patentId>US2009137792</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>synthesis of iduronate and longer HS oligosaccharides</gtr:title><gtr:yearProtectionGranted>2009</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>bevacizumab in ovarian cancer for NICE</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:id>F21F8739-E928-4C21-BB4F-E4FC12111832</gtr:id><gtr:type>Participation in a national consultation</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>HS oligosaccharides. we are modifying the structures to improve activity and in so doing have discovered much greater structural specificity than previously suspected</gtr:description><gtr:id>1ACFD307-F9CA-4ED2-9325-301C3EA65387</gtr:id><gtr:impact>as above. the identification of structure-function relationships will generate a platform upon which a new generation of drugs based on the inhibition of the HS-GF relationship.</gtr:impact><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>HS oligosaccharides</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2011</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>We have made families of structurally defined heparan sulphate oligosaccharides</gtr:description><gtr:id>8EEF96ED-5C7B-49B3-8F86-4DF758332DD7</gtr:id><gtr:impact>Our data suggest that there may be much greater structural specificity in the HS-growth factor relationship than has been suspected before.</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>synthetic heparan sulphate oligosaccharides</gtr:title><gtr:type>Biological samples</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D86935FA-A6AD-407B-93E2-BA24239F6EC4"><gtr:id>D86935FA-A6AD-407B-93E2-BA24239F6EC4</gtr:id><gtr:title>Issues on fit-for-purpose validation of a panel of ELISAs for application as biomarkers in clinical trials of anti-Angiogenic drugs.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ce8b865cb504a83b250d1f5365034e30"><gtr:id>ce8b865cb504a83b250d1f5365034e30</gtr:id><gtr:otherNames>Brookes K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9CE1A705-AC25-421D-B67E-379195FC16ED"><gtr:id>9CE1A705-AC25-421D-B67E-379195FC16ED</gtr:id><gtr:title>DCE-MRI biomarkers of tumour heterogeneity predict CRC liver metastasis shrinkage following bevacizumab and FOLFOX-6.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5261e64d77ae945d18be26d2f9a33824"><gtr:id>5261e64d77ae945d18be26d2f9a33824</gtr:id><gtr:otherNames>O'Connor JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F162BF22-8385-43B0-941A-AE3663D17C2B"><gtr:id>F162BF22-8385-43B0-941A-AE3663D17C2B</gtr:id><gtr:title>Scalable synthesis of L-iduronic acid derivatives via stereocontrolled cyanohydrin reaction for synthesis of heparin-related disaccharides.</gtr:title><gtr:parentPublicationTitle>Organic letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/45847ebe50cfcf60d4977b6bc361f884"><gtr:id>45847ebe50cfcf60d4977b6bc361f884</gtr:id><gtr:otherNames>Hansen SU</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1523-7052</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/931E83E9-6C7E-4839-B466-92839820A4DE"><gtr:id>931E83E9-6C7E-4839-B466-92839820A4DE</gtr:id><gtr:title>A latent reactive handle for functionalising heparin-like and LMWH deca- and dodecasaccharides.</gtr:title><gtr:parentPublicationTitle>Organic &amp; biomolecular chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1b108ba399454ec071f629b8aea25ffb"><gtr:id>1b108ba399454ec071f629b8aea25ffb</gtr:id><gtr:otherNames>Miller GJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1477-0520</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6559FFA3-4591-4733-B518-C9D2BAE777D1"><gtr:id>6559FFA3-4591-4733-B518-C9D2BAE777D1</gtr:id><gtr:title>Biomarkers of angiogenesis and their role in the development of VEGF inhibitors.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7b2773ce0b8cff611563d31271ea10f4"><gtr:id>7b2773ce0b8cff611563d31271ea10f4</gtr:id><gtr:otherNames>Murukesh N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3A826612-3D0A-4CC5-8CE9-C7961E81EF68"><gtr:id>3A826612-3D0A-4CC5-8CE9-C7961E81EF68</gtr:id><gtr:title>Heparan sulphate synthetic and editing enzymes in ovarian cancer.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/29742572dddbfb84be9bfe9730061975"><gtr:id>29742572dddbfb84be9bfe9730061975</gtr:id><gtr:otherNames>Backen AC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FCAA5C94-30A2-43E3-B93B-2D12F1841596"><gtr:id>FCAA5C94-30A2-43E3-B93B-2D12F1841596</gtr:id><gtr:title>Identification of early predictive imaging biomarkers and their relationship to serological angiogenic markers in patients with ovarian cancer with residual disease following cytotoxic therapy.</gtr:title><gtr:parentPublicationTitle>Annals of oncology : official journal of the European Society for Medical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c549528b946fdc1b1f5a4974fc4b326e"><gtr:id>c549528b946fdc1b1f5a4974fc4b326e</gtr:id><gtr:otherNames>Mitchell CL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0923-7534</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/99F930F3-956C-469A-A409-BCBE5C19427B"><gtr:id>99F930F3-956C-469A-A409-BCBE5C19427B</gtr:id><gtr:title>Heparanase gene haplotype (CGC) is associated with stage of disease in patients with ovarian carcinoma.</gtr:title><gtr:parentPublicationTitle>Cancer science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a6a125bf29dfa916384e19e97da74c24"><gtr:id>a6a125bf29dfa916384e19e97da74c24</gtr:id><gtr:otherNames>Ralph S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1347-9032</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/14D0A540-C679-4FCE-BE6E-35BFB0447070"><gtr:id>14D0A540-C679-4FCE-BE6E-35BFB0447070</gtr:id><gtr:title>Synthesis of a heparin-related GlcN-IdoA sulfation-site variable disaccharide library and analysis by Raman and ROA spectroscopy.</gtr:title><gtr:parentPublicationTitle>Carbohydrate research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1b108ba399454ec071f629b8aea25ffb"><gtr:id>1b108ba399454ec071f629b8aea25ffb</gtr:id><gtr:otherNames>Miller GJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0008-6215</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D4FAA3F1-6C55-4A1E-B1FD-736256328DF9"><gtr:id>D4FAA3F1-6C55-4A1E-B1FD-736256328DF9</gtr:id><gtr:title>Small-molecule-induced clustering of heparan sulfate promotes cell adhesion.</gtr:title><gtr:parentPublicationTitle>Journal of the American Chemical Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d6f188b6a458838d05a0af11a6f4fb3a"><gtr:id>d6f188b6a458838d05a0af11a6f4fb3a</gtr:id><gtr:otherNames>Takemoto N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0002-7863</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6E31A90F-EEA8-4E21-8675-0A86DEA71AC2"><gtr:id>6E31A90F-EEA8-4E21-8675-0A86DEA71AC2</gtr:id><gtr:title>Quantitative imaging biomarkers in the clinical development of targeted therapeutics: current and future perspectives.</gtr:title><gtr:parentPublicationTitle>The Lancet. Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5261e64d77ae945d18be26d2f9a33824"><gtr:id>5261e64d77ae945d18be26d2f9a33824</gtr:id><gtr:otherNames>O'Connor JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1470-2045</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/97D9A0ED-B2D5-446D-AA2C-8FA312AB7519"><gtr:id>97D9A0ED-B2D5-446D-AA2C-8FA312AB7519</gtr:id><gtr:title>Enhancing fraction predicts clinical outcome following first-line chemotherapy in patients with epithelial ovarian carcinoma.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5261e64d77ae945d18be26d2f9a33824"><gtr:id>5261e64d77ae945d18be26d2f9a33824</gtr:id><gtr:otherNames>O'Connor JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DF6A7607-F8D9-4E3D-93DE-D26E4C46E4E6"><gtr:id>DF6A7607-F8D9-4E3D-93DE-D26E4C46E4E6</gtr:id><gtr:title>Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5261e64d77ae945d18be26d2f9a33824"><gtr:id>5261e64d77ae945d18be26d2f9a33824</gtr:id><gtr:otherNames>O'Connor JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7C21B611-3A8B-47A1-A9BD-A8AF26875EA4"><gtr:id>7C21B611-3A8B-47A1-A9BD-A8AF26875EA4</gtr:id><gtr:title>Lymphatic vessel density, microvessel density and lymphangiogenic growth factor expression in colorectal cancer.</gtr:title><gtr:parentPublicationTitle>Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9b2e8647c366fd9f3b84d7598a63b0c1"><gtr:id>9b2e8647c366fd9f3b84d7598a63b0c1</gtr:id><gtr:otherNames>Duff SE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1462-8910</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DEB8532D-1ABC-4252-81EC-A666F3BC2737"><gtr:id>DEB8532D-1ABC-4252-81EC-A666F3BC2737</gtr:id><gtr:title>First gram-scale synthesis of a heparin-related dodecasaccharide.</gtr:title><gtr:parentPublicationTitle>Organic letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/45847ebe50cfcf60d4977b6bc361f884"><gtr:id>45847ebe50cfcf60d4977b6bc361f884</gtr:id><gtr:otherNames>Hansen SU</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1523-7052</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/37F71385-010B-49EF-A913-295AB3C8AEDE"><gtr:id>37F71385-010B-49EF-A913-295AB3C8AEDE</gtr:id><gtr:title>Imaging tumor vascular heterogeneity and angiogenesis using dynamic contrast-enhanced magnetic resonance imaging.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4cde5a728a30fccb64991e2d25d7a59d"><gtr:id>4cde5a728a30fccb64991e2d25d7a59d</gtr:id><gtr:otherNames>Jackson A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3B415273-E2B2-410E-89EF-A18DFA9AC645"><gtr:id>3B415273-E2B2-410E-89EF-A18DFA9AC645</gtr:id><gtr:title>Synthesis of L-iduronic acid derivatives via [3.2.1] and [2.2.2] L-iduronic lactones from bulk glucose-derived cyanohydrin hydrolysis: a reversible conformationally switched superdisarmed/rearmed lactone route to heparin disaccharides.</gtr:title><gtr:parentPublicationTitle>The Journal of organic chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/45847ebe50cfcf60d4977b6bc361f884"><gtr:id>45847ebe50cfcf60d4977b6bc361f884</gtr:id><gtr:otherNames>Hansen SU</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-3263</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BF5C496B-9865-40AA-BE0E-ED47F4190E0C"><gtr:id>BF5C496B-9865-40AA-BE0E-ED47F4190E0C</gtr:id><gtr:title>Synthetic heparan sulfate oligosaccharides inhibit endothelial cell functions essential for angiogenesis.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0115694f3825ebf31244b421484b7bae"><gtr:id>0115694f3825ebf31244b421484b7bae</gtr:id><gtr:otherNames>Cole CL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CB36BB05-1098-4097-BE0A-391E1679AAED"><gtr:id>CB36BB05-1098-4097-BE0A-391E1679AAED</gtr:id><gtr:title>The development of anti-angiogenic heparan sulfate oligosaccharides.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/de2ffbfbd3a541e8a4ed5d196f67c490"><gtr:id>de2ffbfbd3a541e8a4ed5d196f67c490</gtr:id><gtr:otherNames>Jayson GC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/37EF4B4B-C775-44B1-8A1E-3666895AD9A6"><gtr:id>37EF4B4B-C775-44B1-8A1E-3666895AD9A6</gtr:id><gtr:title>Ovarian cancer cell heparan sulfate 6-O-sulfotransferases regulate an angiogenic program induced by heparin-binding epidermal growth factor (EGF)-like growth factor/EGF receptor signaling.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0115694f3825ebf31244b421484b7bae"><gtr:id>0115694f3825ebf31244b421484b7bae</gtr:id><gtr:otherNames>Cole CL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/464E923E-D879-4829-A746-10B891DCDC91"><gtr:id>464E923E-D879-4829-A746-10B891DCDC91</gtr:id><gtr:title>Synthetic heparan sulfate dodecasaccharides reveal single sulfation site interconverts CXCL8 and CXCL12 chemokine biology.</gtr:title><gtr:parentPublicationTitle>Chemical communications (Cambridge, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/de2ffbfbd3a541e8a4ed5d196f67c490"><gtr:id>de2ffbfbd3a541e8a4ed5d196f67c490</gtr:id><gtr:otherNames>Jayson GC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1359-7345</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AC993583-5A1D-4EF4-B305-F8628F54913E"><gtr:id>AC993583-5A1D-4EF4-B305-F8628F54913E</gtr:id><gtr:title>Inhibition of FGFR2 and FGFR1 increases cisplatin sensitivity in ovarian cancer.</gtr:title><gtr:parentPublicationTitle>Cancer biology &amp; therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/22b06ec69d0137bb4a231178d116e464"><gtr:id>22b06ec69d0137bb4a231178d116e464</gtr:id><gtr:otherNames>Cole C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1538-4047</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/67555B26-E89F-46EE-99D7-65268196B0A3"><gtr:id>67555B26-E89F-46EE-99D7-65268196B0A3</gtr:id><gtr:title>Tetrasaccharide iteration synthesis of a heparin-like dodecasaccharide and radiolabelling for in vivo tissue distribution studies.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/45847ebe50cfcf60d4977b6bc361f884"><gtr:id>45847ebe50cfcf60d4977b6bc361f884</gtr:id><gtr:otherNames>Hansen SU</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/02DFBFCE-D13E-4948-B467-4D566D28C9F6"><gtr:id>02DFBFCE-D13E-4948-B467-4D566D28C9F6</gtr:id><gtr:title>Antiangiogenic drugs in ovarian cancer.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e83c483da3978143ef19cbaff23ff7bd"><gtr:id>e83c483da3978143ef19cbaff23ff7bd</gtr:id><gtr:otherNames>Kumaran GC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D20A8695-9498-4599-AE64-4E42B9A55AC5"><gtr:id>D20A8695-9498-4599-AE64-4E42B9A55AC5</gtr:id><gtr:title>Heparin octasaccharides inhibit angiogenesis in vivo.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a0626423e5e9bcaf17b17bbe95041d13"><gtr:id>a0626423e5e9bcaf17b17bbe95041d13</gtr:id><gtr:otherNames>Hasan J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1B2A893A-8B65-438D-92B0-17776A4CF59F"><gtr:id>1B2A893A-8B65-438D-92B0-17776A4CF59F</gtr:id><gtr:title>Modular synthesis of heparin-related tetra-, hexa- and octasaccharides with differential o-6 protections: programming for regiodefined 6-o-modifications.</gtr:title><gtr:parentPublicationTitle>Molecules (Basel, Switzerland)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/06885bc03841702a6aa73c47cbfe184b"><gtr:id>06885bc03841702a6aa73c47cbfe184b</gtr:id><gtr:otherNames>Bar?th M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1420-3049</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A3EF68BA-8FA4-4918-81A5-3A2438AA3D54"><gtr:id>A3EF68BA-8FA4-4918-81A5-3A2438AA3D54</gtr:id><gtr:title>VEGF inhibitors and advanced ovarian cancer.</gtr:title><gtr:parentPublicationTitle>The Lancet. Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0d75cc06ef727d51e77a523ce8de125d"><gtr:id>0d75cc06ef727d51e77a523ce8de125d</gtr:id><gtr:otherNames>Jayson G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1470-2045</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/30EA0728-3191-4A68-BE43-AACC0925B51C"><gtr:id>30EA0728-3191-4A68-BE43-AACC0925B51C</gtr:id><gtr:title>Segregation of late outgrowth endothelial cells into functional endothelial CD34- and progenitor-like CD34+ cell populations.</gtr:title><gtr:parentPublicationTitle>Angiogenesis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d57e44aae00d00466b9df35181807756"><gtr:id>d57e44aae00d00466b9df35181807756</gtr:id><gtr:otherNames>Ferreras C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0969-6970</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0902173</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>DD81206B-5EB4-4BCC-AEF7-808A64606E0E</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.2  Cellular and gene therapies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>